microRNAs distinctively regulate vascular smooth muscle and endothelial cells: Functional implications in angiogenesis, atherosclerosis, and in-stent restenosis

Advances in Experimental Medicine and Biology

Volumn 887, Issue , 2015, Pages 53-77

  Santulli, Gaetano ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Angiogenesis; Angioplasty; Atherosclerosis; Circulation; DES; Diabetes; Endothelium; Inflammation; miR 126; miR 143 145; Myocardin; Myoregulin; Neointima; Restenosis; Stent; Thrombosis; VSMC

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN; CALPONIN; DNA; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; KRUPPEL LIKE FACTOR 5; MICRORNA; MICRORNA 126; MICRORNA 143; MICRORNA 145; MYOCARDIN; MYOLIMUS; MYOSIN HEAVY CHAIN; NOVOLIMUS; PLATELET DERIVED GROWTH FACTOR BB; RAPAMYCIN; SERUM RESPONSE FACTOR; TRANSFORMING GROWTH FACTOR BETA; UMIROLIMUS; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ZOTAROLIMUS;

ANGIOGENESIS; ATHEROSCLEROSIS; BARE METAL STENT; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL TONE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DNA METHYLATION; DOWN REGULATION; DRUG ELUTING STENT; DRUG STRUCTURE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; IN-STENT RESTENOSIS; MEDICAL DECISION MAKING; MEDICAL DEVICE COMPLICATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STENT THROMBOSIS; TRANSLATION REGULATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE CELL; ADVERSE EFFECTS; ANGIOPLASTY; ANIMAL; CYTOLOGY; GENETICS; GRAFT OCCLUSION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SMOOTH MUSCLE CELL; STENT; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY; ANIMALS; ATHEROSCLEROSIS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GRAFT OCCLUSION, VASCULAR; HUMANS; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RNA, UNTRANSLATED; STENTS; VASCULAR REMODELING;

EID: 84949781338     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-22380-3_4     Document Type: Chapter

References (255)

1. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, et al. AKT participates in endothelial dysfunction in hypertension. Circulation. 2004; 109: 2587-93.
2. Santulli G, Wronska A, Uryu K, Diacovo TG, Gao M, Marx SO, et al. A selective microRNAbased strategy inhibits restenosis while preserving endothelial function. J Clin Invest. 2014; 124: 4102-14.
3. Cimpean A, Ribatti D, Raica M. A historical appraisal of angiogenesis assays since Judah Folkman and before…. In: Santulli G, editor. Angiogenesis: insights from a systematic overview. New York: Nova Science; 2013. p. 31-50.
4. Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, et al. CaMK4 gene deletion induces hypertension. J Am Heart Assoc. 2012; 1, e001081.
5. Santulli G, Trimarco B, Iaccarino G. G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. High Blood Press Cardiovasc Prev. 2013; 20: 5-12.
6. Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, et al. The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci U S A. 2008; 105: 17818-23.
7. Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol. 2014; 5: 4.
8. Santulli G. β-blockers in diabetic patients with heart failure. JAMA Intern Med. 2015; 175(4): 657.
9. Santulli G. Effects of low-carbohydrate and low-fat diets. Ann Intern Med. 2015; 162: 392.
10. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS, et al. Integrating cardiac PIP(3) and cAMP signaling through a PKA anchoring function of p110gamma. Mol Cell. 2011; 42: 84-95.
11. Santulli G. Adrenal signaling in heart failure: something more than a distant ship's smoke on the horizon. Hypertension. 2014; 63: 215-6.
12. van Lieshout JJ, Wieling W, Karemaker JM, Eckberg DL. The vasovagal response. Clin Sci. 1991; 81: 575-86.
13. Santulli G, Ciccarelli M, Trimarco B, Iaccarino G. Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the beta adrenergic system. Front Physiol. 2013; 4: 209.
14. Wronska A, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxf). 2015; 213: 60-83.
15. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014; 42: D68-73.
16. Anderson DM, Anderson KM, Chang CL, Makarewich CA, Nelson BR, McAnally JR, et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell. 2015; 160: 595-606.
17. Andrews SJ, Rothnagel JA. Emerging evidence for functional peptides encoded by short open reading frames. Nat Rev Genet. 2014; 15: 193-204.
18. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science. 2005; 309: 1559-63.
19. Lee LJ, Hughes TR, Frey BJ. How many new genes are there? Science. 2006; 311: 1709-11; author reply-1711.
20. Santulli G, Ciccarelli M, Palumbo G, Campanile A, Galasso G, Ziaco B, et al. In vivo properties of the proangiogenic peptide QK. J Transl Med. 2009; 7: 41.
21. Ciccarelli M, Santulli G, Campanile A, Galasso G, Cervero P, Altobelli GG, et al. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol. 2008; 153: 936-46.
22. Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, et al. Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit. J Transl Med. 2011; 9: 7.
23. Berthod F. Fibroblasts and endothelial cells: the basic angiogenic unit. In: Santulli G, editor. Angiogenesis: insights from a systematic overview. New York: Nova Science; 2013. p. 145-58.
24. Yamamoto S, Niida S, Azuma E, Yanagibashi T, Muramatsu M, Huang TT, et al. Inflammationinduced endothelial cell-derived extracellular vesicles modulate the cellular status of pericytes. Sci Rep. 2015; 5: 8505.
25. Matarese A, Santulli G. Angiogenesis in chronic obstructive pulmonary disease: a translational appraisal. Transl Med UniSa. 2012; 3: 49-56.
26. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009; 460: 705-10.
27. Iio A, Nakagawa Y, Hirata I, Naoe T, Akao Y. Identification of non-coding RNAs embracing microRNA-143/145 cluster. Mol Cancer. 2010; 9: 136.
28. Boucher JM, Peterson SM, Urs S, Zhang C, Liaw L. The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells. J Biol Chem. 2011; 286: 28312-21.
29. Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G, et al. Downregulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem. 2011; 286: 28097-110.
30. Batliner J, Buehrer E, Fey MF, Tschan MP. Inhibition of the miR-143/145 cluster attenuated neutrophil differentiation of APL cells. Leuk Res. 2012; 36: 237-40.
31. Iio A, Takagi T, Miki K, Naoe T, Nakayama A, Akao Y. DDX6 post-transcriptionally downregulates miR-143/145 expression through host gene NCR143/145 in cancer cells. Biochim Biophys Acta. 1829; 2013: 1102-10.
32. Medrano S, Sequeira-Lopez ML, Gomez RA. Deletion of the miR-143/145 cluster leads to hydronephrosis in mice. Am J Pathol. 2014; 184: 3226-38.
33. Dahan D, Ekman M, Larsson-Callerfelt AK, Turczynska K, Boettger T, Braun T, et al. Induction of angiotensin-converting enzyme after miR-143/145 deletion is critical for impaired smooth muscle contractility. Am J Physiol Cell Physiol. 2014; 307: C1093-101.
34. Kent OA, McCall MN, Cornish TC, Halushka MK. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 2014; 42: 7528-38.
35. Chivukula RR, Shi G, Acharya A, Mills EW, Zeitels LR, Anandam JL, et al. An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell. 2014; 157: 1104-16.
36. Kojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, et al. The tumorsuppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet. 2014; 59: 78-87.
37. Zhao W, Zheng XL, Peng DQ, Zhao SP. Myocyte enhancer factor 2A regulates hydrogen peroxide-induced senescence of vascular smooth muscle cells via microRNA-143. J Cell Physiol. 2015; 230: 2202-11.
38. Bhattachariya A, Dahan D, Ekman M, Boettger T, Braun T, Sward K, et al. Spontaneous activity and stretch-induced contractile differentiation are reduced in vascular smooth muscle of miR-143/145 knockout mice. Acta Physiol (Oxf). 2015. doi: 10. 1111/apha. 12536.
39. Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, Martinez FO, et al. Cholesterol loading reprograms the MicroRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler Thromb Vasc Biol. 2015; 35: 535-46.
40. Koo S, Martin G, Toussaint LG. MicroRNA-145 promotes the phenotype of human glioblastoma cells selected for invasion. Anticancer Res. 2015; 35: 3209-15.
41. Avgeris M, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG, Scorilas A. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis. 2015; 36: 528-37.
42. Riches K, Alshanwani AR, Warburton P, O'Regan DJ, Ball SG, Wood IC, et al. Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol. 2014; 74: 240-50.
43. Sala F, Aranda JF, Rotllan N, Ramirez CM, Aryal B, Elia L, et al. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost. 2014; 112: 796-802.
44. Engelhardt S, Leierseder S. Coinciding functions for miR-145 in vascular smooth muscle and cardiac fibroblasts. J Mol Cell Cardiol. 2013; 65: 105-7.
45. Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, Hein L, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009; 119: 2634-47.
46. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, et al. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009; 16: 1590-8.
47. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell. 2001; 105: 851-62.
48. Wang DZ, Li S, Hockemeyer D, Sutherland L, Wang Z, Schratt G, et al. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci U S A. 2002; 99: 14855-60.
49. Liu X, Cheng Y, Yang J, Qin S, Chen X, Tang X, et al. Flank sequences of miR-145/143 and their aberrant expression in vascular disease: mechanism and therapeutic application. J Am Heart Assoc. 2013; 2, e000407.
50. Quintavalle M, Elia L, Condorelli G, Courtneidge SA. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol. 2010; 189: 13-22.
51. Climent M, Quintavalle M, Miragoli M, Chen J, Condorelli G, Elia L. TGFbeta triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Circ Res. 2015; 116: 1753-64.
52. Thayanithy V, Dickson EL, Steer C, Subramanian S, Lou E. Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes. Transl Res. 2014; 164: 359-65.
53. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008; 15: 272-84.
54. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 2008; 47: 939-46.
55. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ, et al. Attribution of vascular phenotypes of the murine Egfl 7 locus to the microRNA miR-126. Development. 2008; 135: 3989-93.
56. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med (Berl). 2008; 86: 313-22.
57. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15: 261-71.
58. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, et al. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun. 2008; 377: 136-40.
59. Zhao C, Li Y, Zhang M, Yang Y, Chang L. miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell. 2015; 28: 91-9.
60. Khella HW, Scorilas A, Mozes R, Mirham L, Lianidou E, Krylov SN, et al. Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma. Am J Pathol. 2015; 185: 693-703.
61. Yang Y, Song KL, Chang H, Chen L. Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer. Diagn Pathol. 2014; 9: 220.
62. Bijkerk R, van Solingen C, de Boer HC, de Vries DK, Monge M, van Oeveren-Rietdijk A, et al. Silencing of miRNA-126 in kidney ischemia reperfusion is associated with elevated SDF-1 levels and mobilization of Sca-1+/Lin-progenitor cells. Microrna. 2014; 3: 144-9.
63. Lonvik K, Sorbye SW, Nilsen MN, Paulssen RH. Prognostic value of the MicroRNA regulators dicer and Drosha in non-small-cell lung cancer: co-expression of Drosha and miR-126 predicts poor survival. BMC Clin Pathol. 2014; 14: 45.
64. Liu R, Gu J, Jiang P, Zheng Y, Liu X, Jiang X, et al. DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res. 2015; 21: 854-63.
65. Jiang L, Tao C, He A, He X. Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol. 2014; 12: 383.
66. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009; 66: 169-75.
67. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010; 298: 50-63.
68. Harnprasopwat R, Ha D, Toyoshima T, Lodish H, Tojo A, Kotani A. Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126. Biochem Biophys Res Commun. 2010; 399: 117-22.
69. Meister J, Schmidt MH. miR-126 and miR-126*: new players in cancer. ScientificWorldJournal. 2010; 10: 2090-100.
70. Oglesby IK, Bray IM, Chotirmall SH, Stallings RL, O'Neill SJ, McElvaney NG, et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol. 2010; 184: 1702-9.
71. Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun. 2010; 391: 1483-9.
72. Chen JJ, Zhou SH. Mesenchymal stem cells overexpressing MiR-126 enhance ischemic angiogenesis via the AKT/ERK-related pathway. Cardiol J. 2011; 18: 675-81.
73. Collison A, Herbert C, Siegle JS, Mattes J, Foster PS, Kumar RK. Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target. BMC Pulm Med. 2011; 11: 29.
74. Cui W, Li Q, Feng L, Ding W. MiR-126-3p regulates progesterone receptors and involves development and lactation of mouse mammary gland. Mol Cell Biochem. 2011; 355: 17-25.
75. Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, et al. Independent and tissuespecific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer. 2011; 117: 3193-200.
76. Li XM, Wang AM, Zhang J, Yi H. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol. 2011; 28: 1054-7.
77. Li Z, Chen J. In vitro functional study of miR-126 in leukemia. Methods Mol Biol. 2011; 676: 185-95.
78. Ren G, Kang Y. A one-two punch of miR-126/126* against metastasis. Nat Cell Biol. 2013; 15: 231-3.
79. Schmidt Y, Simunovic F, Strassburg S, Pfeifer D, Stark GB, Finkenzeller G. miR-126 regulates platelet-derived growth factor receptor-alpha expression and migration of primary human osteoblasts. Biol Chem. 2015; 396: 61-70.
80. Togliatto G, Trombetta A, Dentelli P, Gallo S, Rosso A, Cotogni P, et al. Unacylated ghrelin induces oxidative stress resistance in a glucose intolerance and peripheral artery disease mouse model by restoring endothelial cell miR-126 expression. Diabetes. 2015; 64: 1370-82.
81. Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, et al. Efficient detection and purification of cell populations using synthetic microRNA switches. Cell Stem Cell. 2015; 16: 699-711.
82. Feng X, Tan W, Cheng S, Wang H, Ye S, Yu C, et al. Upregulation of microRNA-126 in hepatic stellate cells may affect pathogenesis of liver fibrosis through the NF-kappaB pathway. DNA Cell Biol. 2015; 34(7): 470-80.
83. Rohde JH, Weigand JE, Suess B, Dimmeler S. A universal aptamer chimera for the delivery of functional microRNA-126. Nucleic Acid Ther. 2015; 25: 141-51.
84. Shibayama Y, Kondo T, Ohya H, Fujisawa S, Teshima T, Iseki K. Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients. Oncol Rep. 2015; 33: 2176-82.
85. Hu J, Zeng L, Huang J, Wang G, Lu H. miR-126 promotes angiogenesis and attenuates inflammation after contusion spinal cord injury in rats. Brain Res. 2015; 1608: 191-202.
86. Nakano M, Fukushima Y, Yokota S, Fukami T, Takamiya M, Aoki Y, et al. CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126. Drug Metab Dispos. 2015; 43: 703-12.
87. Meng Q, Wang W, Yu X, Li W, Kong L, Qian A, et al. Upregulation of microRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem. 2015; 116(8): 1613-23.
88. Mocharla P, Briand S, Giannotti G, Dorries C, Jakob P, Paneni F, et al. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood. 2013; 121: 226-36.
89. Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol. 2012; 53: 64-72.
90. Prattichizzo F, Giuliani A, Ceka A, Rippo MR, Bonfigli AR, Testa R, et al. Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clin Epigenetics. 2015; 7(1): 56.
91. Tian HS, Zhou QG, Shao F. Relationship between arterial atheromatous plaque morphology and platelet-associated miR-126 and miR-223 expressions. Asian Pac J Trop Med. 2015; 8: 309-14.
92. Zhang T, Li L, Shang Q, Lv C, Wang C, Su B. Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals. Biochem Biophys Res Commun. 2015; 463(1-2): 60-3.
93. Endo-Takahashi Y, Negishi Y, Nakamura A, Ukai S, Ooaku K, Oda Y, et al. Systemic delivery of miR-126 by miRNA-loaded bubble liposomes for the treatment of hindlimb ischemia. Sci Rep. 2014; 4: 3883.
94. Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ. 2014; 4: 175-84.
95. Yamaguchi T, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, et al. Underexpression of miR-126 and miR-20b in hereditary and nonhereditary colorectal tumors. Oncology. 2014; 87: 58-66.
96. Yan T, Cui K, Huang X, Ding S, Zheng Y, Luo Q, et al. Assessment of therapeutic efficacy of miR-126 with contrast-enhanced ultrasound in preeclampsia rats. Placenta. 2014; 35: 23-9.
97. Goerke SM, Kiefer LS, Stark GB, Simunovic F, Finkenzeller G. miR-126 modulates angiogenic growth parameters of peripheral blood endothelial progenitor cells. Biol Chem. 2015; 396: 245-52.
98. Olivieri F, Bonafe M, Spazzafumo L, Gobbi M, Prattichizzo F, Recchioni R, et al. Age-and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging. 2014; 6: 771-87.
99. McAuley AK, Dirani M, Wang JJ, Connell PP, Lamoureux EL, Hewitt AW. A genetic variant regulating miR-126 is associated with sight threatening diabetic retinopathy. Diab Vasc Dis Res. 2015; 12: 133-8.
100. Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest. 1997; 100: S87-9.
101. Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem. 2007; 282: 37244-55.
102. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008; 454: 56-61.
103. Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Maegdefessel L, et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol. 2011; 226: 1035-43.
104. Chan MC, Hilyard AC, Wu C, Davis BN, Hill NS, Lal A, et al. Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression. EMBO J. 2010; 29: 559-73.
105. Yan J, Stringer SE, Hamilton A, Charlton-Menys V, Gotting C, Muller B, et al. Decorin GAG synthesis and TGF-beta signaling mediate Ox-LDL-induced mineralization of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011; 31: 608-15.
106. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008; 283: 33394-405.
107. Xie C, Huang H, Sun X, Guo Y, Hamblin M, Ritchie RP, et al. MicroRNA-1 regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4. Stem Cells Dev. 2011; 20: 205-10.
108. Huang H, Xie C, Sun X, Ritchie RP, Zhang J, Chen YE. miR-10a contributes to retinoid acidinduced smooth muscle cell differentiation. J Biol Chem. 2010; 285: 9383-9.
109. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A. 2010; 107: 13450-5.
110. Kim S, Kang H. miR-15b induced by platelet-derived growth factor signaling is required for vascular smooth muscle cell proliferation. BMB Rep. 2013; 46: 550-4.
111. Kee HJ, Kim GR, Cho SN, Kwon JS, Ahn Y, Kook H, et al. miR-18a-5p microRNA increases vascular smooth muscle cell differentiation by downregulating syndecan4. Korean Circ J. 2014; 44: 255-63.
112. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res. 2010; 3: 251-5.
113. Young MR, Santhanam AN, Yoshikawa N, Colburn NH. Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue? Mol Interv. 2010; 10: 76-9.
114. Choe N, Kwon JS, Kim JR, Eom GH, Kim Y, Nam KI, et al. The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis. 2013; 229: 348-55.
115. Kinoshita T, Nohata N, Fuse M, Hanazawa T, Kikkawa N, Fujimura L, et al. Tumor suppressive microRNA-133a regulates novel targets: moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2012; 418: 378-83.
116. Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett. 2014; 588: 1168-77.
117. Kim MH, Ham O, Lee SY, Choi E, Lee CY, Park JH, et al. MicroRNA-365 inhibits the proliferation of vascular smooth muscle cells by targeting cyclin D1. J Cell Biochem. 2014; 115: 1752-61.
118. Merlet E, Atassi F, Motiani RK, Mougenot N, Jacquet A, Nadaud S, et al. miR-424/322 regulates vascular smooth muscle cell phenotype and neointimal formation in the rat. Cardiovasc Res. 2013; 98: 458-68.
119. Sun Y, Chen D, Cao L, Zhang R, Zhou J, Chen H, et al. MiR-490-3p modulates the proliferation of vascular smooth muscle cells induced by ox-LDL through targeting PAPP-A. Cardiovasc Res. 2013; 100: 272-9.
120. Li P, Liu Y, Yi B, Wang G, You X, Zhao X, et al. MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1. Cardiovasc Res. 2013; 99: 185-93.
121. Li P, Zhu N, Yi B, Wang N, Chen M, You X, et al. MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ Res. 2013; 113: 1117-27.
122. Korff T, Pfisterer L, Schorpp-Kistner M. miR-663 and the miRaculous vascular smooth muscle phenotypic switch. Circ Res. 2013; 113: 1102-5.
123. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007; 100: 1579-88.
124. Silvestri P, Rigattieri S, Loschiavo P. Does the effect of microRNAs in vascular neointimal formation depend on cell cycle phase? Circ Res. 2008; 102(9): e101; author reply e102.
125. Davis-Dusenbery BN, Wu C, Hata A. Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol. 2011; 31: 2370-7.
126. Talasila A, Yu H, Ackers-Johnson M, Bot M, van Berkel T, Bennett MR, et al. Myocardin regulates vascular response to injury through miR-24/-29a and platelet-derived growth factor receptor-beta. Arterioscler Thromb Vasc Biol. 2013; 33: 2355-65.
127. Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res. 2013; 113: 1231-41.
128. Bai Y, Wang L, Sun L, Ye P, Hui R. Circulating microRNA-26a: potential predictors and therapeutic targets for non-hypertensive intracerebral hemorrhage. Med Hypotheses. 2011; 77: 488-90.
129. Liu X, Cheng Y, Chen X, Yang J, Xu L, Zhang C. MicroRNA-31 regulated by the extracellular regulated kinase is involved in vascular smooth muscle cell growth via large tumor suppressor homolog 2. J Biol Chem. 2011; 286: 42371-80.
130. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010; 120: 1298-309.
131. Wang J, Yan CH, Li Y, Xu K, Tian XX, Peng CF, et al. MicroRNA-31 controls phenotypic modulation of human vascular smooth muscle cells by regulating its target gene cellular repressor of E1A-stimulated genes. Exp Cell Res. 2013; 319: 1165-75.
132. Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med. 2013; 5: 949-66.
133. Togliatto G, Trombetta A, Dentelli P, Rosso A, Brizzi MF. MIR221/MIR222-driven posttranscriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose-and AGEmediated vascular cell damage. Diabetologia. 2011; 54: 1930-40.
134. Kothapalli D, Castagnino P, Rader DJ, Phillips MC, Lund-Katz S, Assoian RK. Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222. Atherosclerosis. 2013; 227: 65-71.
135. Mackenzie NC, Staines KA, Zhu D, Genever P, Macrae VE. miRNA-221 and miRNA-222 synergistically function to promote vascular calcification. Cell Biochem Funct. 2014; 32: 209-16.
136. Gao S, Wassler M, Zhang L, Li Y, Wang J, Zhang Y, et al. MicroRNA-133a regulates insulinlike growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis. 2014; 232: 171-9.
137. Zhang CF, Kang K, Li XM, Xie BD. MicroRNA-136 promotes vascular muscle cell proliferation through the ERK1/2 pathway by targeting PPP2R2A in atherosclerosis. Curr Vasc Pharmacol. 2014; 13(3): 405-12.
138. Hu W, Wang M, Yin H, Yao C, He Q, Yin L, et al. MicroRNA-1298 is regulated by DNA methylation and affects vascular smooth muscle cell function by targeting connexin 43. Cardiovasc Res. 2015; 107: 534-45.
139. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet. 1996; 347: 305-7.
140. O'Sullivan JF, Martin K, Caplice NM. Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". J Am Coll Cardiol. 2011; 57: 383-9.
141. Vanhoutte PM. Endothelium-derived free radicals: for worse and for better. J Clin Invest. 2001; 107: 23-5.
142. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997; 100: 2153-7.
143. Iaccarino D, Politi L, Rossi R, Sgura F, Monopoli D, Modena MG, et al. Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts reendothelialization in patients with non-ST-elevation acute coronary syndromes-a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation. J Cardiovasc Med (Hagerstown). 2010; 11: 536-43.
144. Mei H, Campbell JM, Paddock CM, Lertkiatmongkol P, Mosesson MW, Albrecht RM, et al. Regulation of endothelial cell barrier function by antibody-driven affinity modulation of PECAM-1. J Biol Chem. 2014; 289(30): 20836-44.
145. Pannekoek WJ, Post A, Bos JL. Rap1 signaling in endothelial barrier control. Cell Adh Migr. 2014; 8(2): 100-7.
146. Gadang V, Konaniah E, Hui DY, Jaeschke A. Mixed-lineage kinase 3 deficiency promotes neointima formation through increased activation of the RhoA pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2014; 34: 1429-36.
147. Popma JJ, Topol EJ. Factors influencing restenosis after coronary angioplasty. Am J Med. 1990; 88: 16N-24.
148. Faxon DP, Sanborn TA, Haudenschild CC. Mechanism of angioplasty and its relation to restenosis. Am J Cardiol. 1987; 60: 5B-9.
149. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biological responses in stented arteries. Cardiovasc Res. 2013; 99: 353-63.
150. De Caterina R, Massaro M, Scoditti E, Annunziata CM. Pharmacological modulation of vascular inflammation in atherothrombosis. Ann N Y Acad Sci. 2010; 1207: 23-31.
151. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003; 1: 1343-8.
152. Rhee JW, Wu JC. Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc Med. 2013; 23: 39-45.
153. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012; 9: 439-53.
154. Hagensen MK, Raarup MK, Mortensen MB, Thim T, Nyengaard JR, Falk E, et al. Circulating endothelial progenitor cells do not contribute to regeneration of endothelium after murine arterial injury. Cardiovasc Res. 2012; 93: 223-31.
155. Tsuzuki M. Bone marrow-derived cells are not involved in reendothelialized endothelium as endothelial cells after simple endothelial denudation in mice. Basic Res Cardiol. 2009; 104: 601-11.
156. Cevese A. Totipotent stem cells could do everything … or else nothing: the case of vascular reendothelialization. Cardiovasc Res. 2012; 93: 211-2.
157. Pearson JD. Endothelial progenitor cells-hype or hope? J Thromb Haemost. 2009; 7: 255-62.
158. Jimenez JM, Prasad V, Yu MD, Kampmeyer CP, Kaakour AH, Wang PJ, et al. Macro-and microscale variables regulate stent haemodynamics, fibrin deposition and thrombomodulin expression. J R Soc Interface. 2014; 11(94): 20131079.
159. Alexander RW. Getting stents to go with the flow. J Clin Invest. 2004; 113: 1532-4.
160. Liuzzo JP, Ambrose JA, Coppola JT. Sirolimus-and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol. 2005; 17: 497-502.
161. Simard T, Hibbert B, Ramirez FD, Froeschl M, Chen YX, O'Brien ER. The evolution of coronary stents: a brief review. Can J Cardiol. 2014; 30: 35-45.
162. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012; 379: 1393-402.
163. Di Lorenzo E, Carbone G, Sauro L, Casafina A, Capasso M, Sauro R. Bare-metal stents versus drug-eluting stents for primary angioplasty: long-term outcome. Curr Cardiol Rep. 2011; 13: 459-64.
164. Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol. 2010; 7: 194-203.
165. Huang KN, Grandi SM, Filion KB, Eisenberg MJ. Late and very late stent thrombosis in patients with second-generation drug-eluting stents. Can J Cardiol. 2013; 29: 1488-94.
166. Siddiqi OK, Faxon DP. Very late stent thrombosis: current concepts. Curr Opin Cardiol. 2012; 27: 634-41.
167. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519-21.
168. Rossini R, Baroni M, Musumeci G, Gavazzi A. Oral antiplatelet therapy after drug-eluting stent implantation: adherence and side-effects. J Cardiovasc Med (Hagerstown). 2013; 14: 81-90.
169. Dehmer GJ, Smith KJ. Drug-eluting coronary artery stents. Am Fam Physician. 2009; 80: 1245-51.
170. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation. 2013; 128: 2026-38.
171. Deb A, Patterson C. Hard luck stories: the reality of endothelial progenitor cells continues to fall short of the promise. Circulation. 2010; 121: 850-2.
172. Hagensen MK, Shim J, Thim T, Falk E, Bentzon JF. Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis. Circulation. 2010; 121: 898-905.
173. Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc. 2014; 3, e001249.
174. Santulli G. Angiogenesis: insights from a systematic overview. New York: Nova Science; 2013.
175. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012; 31: 3513-23.
176. Qin B, Yang H, Xiao B. Role of microRNAs in endothelial inflammation and senescence. Mol Biol Rep. 2012; 39: 4509-18.
177. Kumar S, Kim CW, Simmons RD, Jo H. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs. Arterioscler Thromb Vasc Biol. 2014; 34: 2206-16.
178. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23-27-24 clusters. Proc Natl Acad Sci U S A. 2011; 108: 8287-92.
179. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature. 2010; 464: 1196-200.
180. Ye X, Hemida MG, Qiu Y, Hanson PJ, Zhang HM, Yang D. MiR-126 promotes coxsackievirus replication by mediating cross-talk of ERK1/2 and Wnt/beta-catenin signal pathways. Cell Mol Life Sci. 2013; 70: 4631-44.
181. Taverna S, Amodeo V, Saieva L, Russo A, Giallombardo M, De Leo G, et al. Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells. Mol Cancer. 2014; 13: 169.
182. Liu LY, Wang W, Zhao LY, Guo B, Yang J, Zhao XG, et al. Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol. 2014; 45: 1257-65.
183. Wang Z, Yin B, Wang B, Ma Z, Liu W, Lv G. MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3. Oncol Res. 2013; 21: 145-54.
184. Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, et al. MicroRNA217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 2009; 120: 1524-32.
185. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013; 19: 74-82.
186. Katz G, Pobezinsky LA, Jeurling S, Shinzawa M, Van Laethem F, Singer A. T cell receptor stimulation impairs IL-7 receptor signaling by inducing expression of the microRNA miR-17 to target Janus kinase 1. Sci Signal. 2014; 7: ra83.
187. Jin C, Zhao Y, Yu L, Xu S, Fu G. MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration. FEBS Lett. 2013; 587: 378-85.
188. Zhou J, Wang KC, Wu W, Subramaniam S, Shyy JY, Chiu JJ, et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc Natl Acad Sci U S A. 2011; 108: 10355-60.
189. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011; 124: 720-30.
190. Zhou Q, Anderson C, Zhang H, Li X, Inglis F, Jayagopal A, et al. Repression of choroidal neovascularization through actin cytoskeleton pathways by microRNA-24. Mol Ther. 2014; 22: 378-89.
191. Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin alpha5 expression. Am J Pathol. 2013; 182: 1876-89.
192. Chen Z, Wen L, Martin M, Hsu CY, Fang L, Lin FM, et al. Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of microRNA-92a. Circulation. 2015; 131: 805-14.
193. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem. 2011; 286: 2047-56.
194. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4: 2427.
195. Liu X, Cheng Y, Yang J, Xu L, Zhang C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol. 2012; 52: 245-55.
196. Nicoli S, Knyphausen CP, Zhu LJ, Lakshmanan A, Lawson ND. miR-221 is required for endothelial tip cell behaviors during vascular development. Dev Cell. 2012; 22: 418-29.
197. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006; 108: 3068-71.
198. Patella F, Leucci E, Evangelista M, Parker B, Wen J, Mercatanti A, et al. MiR-492 impairs the angiogenic potential of endothelial cells. J Cell Mol Med. 2013; 17: 1006-15.
199. Welten SM, Bastiaansen AJ, de Jong RC, de Vries MR, Peters EA, Boonstra MC, et al. Inhibition of 14q32 microRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia. Circ Res. 2014; 115: 696-708.
200. Santulli G. Coronary heart disease risk factors and mortality. JAMA. 2012; 307: 1137.
201. Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. J Cardiovasc Dis (JCvD). 2013; 1: 1-2.
202. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff Jr DC, Hayman LL, et al. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011; 124: 967-90.
203. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121: e46-215.
204. Stefanini GG, Holmes Jr DR. Drug-eluting coronary-artery stents. N Engl J Med. 2013; 368: 254-65.
205. Rao PS, Thapar MK, Kutayli F. Causes of restenosis after balloon valvuloplasty for valvular pulmonary stenosis. Am J Cardiol. 1988; 62: 979-82.
206. Friedman SG. Charles dotter: interventional radiologist. Radiology. 1989; 172: 921-4.
207. Gruentzig AR. Percutaneous transluminal coronary angioplasty. Semin Roentgenol. 1981; 16: 152-3.
208. Meier B, Gruentzig AR, Goebel N, Pyle R, von Gosslar W, Schlumpf M. Assessment of stenoses in coronary angioplasty. Inter-and intraobserver variability. Int J Cardiol. 1983; 3: 159-69.
209. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988; 12: 616-23.
210. Holmes Jr DR, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984; 53: 77C-81.
211. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987; 316: 701-6.
212. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331: 489-95.
213. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331: 496-501.
214. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv. 2011; 4: 104-11.
215. Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest. 2009; 119: 136-45.
216. Suzuki N, Angiolillo DJ, Monteiro C, Shuja S, Futamatsu H, Kawaguchi R, et al. Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents. Int J Cardiol. 2008; 130: 444-8.
217. Jukema JW, Verschuren JJW, Ahmed TAN, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2012; 9: 53-62.
218. Marks AR. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med. 2003; 349: 1307-9.
219. Santulli G, Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics. 2013; 14: 1517-26.
220. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315-23.
221. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350: 221-31.
222. Rollini F, Aprile A, Politi L, Sangiorgi GM. Evaluation of re-endothelization extent at midterm follow-up after drug eluting balloon plus bare metal stent implantation during primary coronary angioplasty: insight from OCT imaging. Minerva Cardioangiol. 2011; 59: 109-12.
223. Jakabcin J, Bystron M, Spacek R, Veselka J, Kvasnak M, Kala P, et al. The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. J Thromb Thrombolysis. 2008; 26: 154-8.
224. Tamburino C, Ussia GP, Zimarino M, Galassi AR, De Caterina R. Early restenosis after drug-eluting stent implantation: a putative role for platelet activation. Can J Cardiol. 2007; 23: 57-9.
225. Wijns WC, Krucoff MW. Increased mortality after implantation of first generation drugeluting stents: seeing the smoke, where is the fire? Eur Heart J. 2006; 27: 2737-9.
226. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48: 193-202.
227. Cassese S, Kastrati A. New-generation drug-eluting stents for patients with myocardial infarction. JAMA. 2012; 308: 814-5.
228. Moss SC, Lightell Jr DJ, Marx SO, Marks AR, Woods TC. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem. 2010; 285: 11991-7.
229. Lange RA, Hillis LD. Second-generation drug-eluting coronary stents. N Engl J Med. 2010; 362: 1728-30.
230. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation. 2001; 103: 2967-72.
231. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996; 98: 2277-83.
232. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008; 52: 1134-40.
233. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 2004; 44: 733-9.
234. Yu PJ, Ferrari G, Pirelli L, Gulkarov I, Galloway AC, Mignatti P, et al. Vascular injury and modulation of MAPKs: a targeted approach to therapy of restenosis. Cell Signal. 2007; 19: 1359-71.
235. Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, Vicinanza C, et al. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol. 2009; 297: H2015-25.
236. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem. 2009; 284: 3728-38.
237. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009; 105: 158-66.
238. McDonald RA, Halliday CA, Miller AM, Diver LA, Dakin RS, Montgomery J, et al. Reducing in-stent restenosis: therapeutic manipulation of miRNA in vascular remodeling and inflammation. J Am Coll Cardiol. 2015; 65: 2314-27.
239. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008; 105: 13027-32.
240. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007; 13: 613-8.
241. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009; 106: 12103-8.
242. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009; 324: 1710-3.
243. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456: 980-4.
244. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005; 438: 685-9.
245. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. 2006; 13: 496-502.
246. Stenvang J, Kauppinen S. MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther. 2008; 8: 59-81.
247. Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014; 6: 1967-84.
248. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013; 172: 962-74.
249. Luck ME, Muljo SA, Collins CB. Prospects for therapeutic targeting of MicroRNAs in human immunological diseases. J Immunol. 2015; 194: 5047-52.
250. Muthiah M, Park IK, Cho CS. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opin Drug Deliv. 2013; 10: 1259-73.
251. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, et al. Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015; 65: 791-801.
252. Sato K, Latib A, Panoulas VF, Kawamoto H, Naganuma T, Miyazaki T, et al. Procedural feasibility and clinical outcomes in propensity-matched patients treated with bioresorbable scaffolds vs new-generation drug-eluting stents. Can J Cardiol. 2015; 31: 328-34.
253. Raungaard B, Jensen LO, Tilsted HH, Christiansen EH, Maeng M, Terkelsen CJ, et al. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradablepolymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet. 2015; 385: 1527-35.
254. Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014; 64: 2343-56.
255. Muthiah M, Islam MA, Cho CS, Hwang JE, Chung IJ, Park IK. Substrate-mediated delivery of microRNA-145 through a polysorbitol-based osmotically active transporter suppresses smooth muscle cell proliferation: implications for restenosis treatment. J Biomed Nanotechnol. 2014; 10: 571-9.